

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PF0412-WO-PCT2	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/EP2023/065930	International filing date (<i>day/month/year</i>) 14 June 2023 (14-06-2023)	(Earliest) Priority Date (<i>day/month/year</i>) 15 June 2022 (15-06-2022)
Applicant UCB BIOPHARMA SRL		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of:

- ☒ the international application in the language in which it was filed
☐ a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

b. ☐ This international search report has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).

c. ☒ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ **Certain claims were found unsearchable** (See Box No. II)

3. ☐ **Unity of invention is lacking** (see Box No III)

4. With regard to the **title**,

- ☐ the text is approved as submitted by the applicant
☒ the text has been established by this Authority to read as follows:

FOLLISTATIN-FC FUSION PROTEINS

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant
☐ the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority

6. With regard to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No. _____
☐ as suggested by the applicant
☐ as selected by this Authority, because the applicant failed to suggest a figure
☐ as selected by this Authority, because this figure better characterizes the invention
b. ☒ none of the figures is to be published with the abstract

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2023/065930

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed.
 - b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13*ter*.1(a)).

☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2023/065930

A. CLASSIFICATION OF SUBJECT MATTER INV. C07K14/47 A61K38/17 C07K16/18 A61K38/00 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07K A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, BIOSIS, EMBASE, WPI Data, CHEM ABS Data, Sequence Search		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2016/311874 A1 (KUMAR RAVINDRA [US] ET AL) 27 October 2016 (2016-10-27)	1-3, 5, 8, 9, 11-16
Y	paragraphs [0004], [0006], [0022], [0101], [0137] - [0144], [0149], [0163] examples 1-2 sequences 2, 4, 57	4, 6, 7, 10
Y	WO 2020/011868 A1 (UCB BIOPHARMA SRL [BE]) 16 January 2020 (2020-01-16) sequences 1, 6 example 1 page 2 figure 2	4, 6, 7, 10
----- -/-		
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
15 September 2023		21/09/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Colling-Ziarko, L

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2023/065930

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MAESHIMA AKITO ET AL: "Follistatin, an Activin Antagonist, Ameliorates Renal Interstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction", BIOMED RESEARCH INTERNATIONAL , vol. 2014 1 January 2014 (2014-01-01), pages 1-10, XP093001908, ISSN: 2314-6133, DOI: 10.1155/2014/376191 Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026945/pdf/BMRI2014-376191.pdf title, abstract -----	1-16
A	WO 2015/187977 A1 (ACCELERON PHARMA INC [US]) 10 December 2015 (2015-12-10) paragraphs [0004] - [0005] example 1 -----	1-16
A	US 9 879 077 B2 (APRILBIO CO LTD [KR]) 30 January 2018 (2018-01-30) title columns 1, 4 example 2.4 -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2023/065930

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2016311874 A1	27-10-2016	AU 2016238254 A1	12-10-2017
		AU 2022202514 A1	12-05-2022
		CA 2980757 A1	29-09-2016
		CN 107636154 A	26-01-2018
		EP 3274457 A1	31-01-2018
		JP 2018510637 A	19-04-2018
		JP 2021097697 A	01-07-2021
		KR 20170129233 A	24-11-2017
		US 2016311874 A1	27-10-2016
		US 2018305427 A1	25-10-2018
		WO 2016154601 A1	29-09-2016
WO 2020011868 A1	16-01-2020	AR 115721 A1	17-02-2021
		AU 2019302995 A1	24-12-2020
		BR 112020025030 A2	23-03-2021
		CA 3103355 A1	16-01-2020
		CL 2020003383 A1	25-06-2021
		CN 112384529 A	19-02-2021
		CO 2021000092 A2	18-01-2021
		EP 3820889 A1	19-05-2021
		IL 279901 A	01-03-2021
		JP 2021530222 A	11-11-2021
		KR 20210032388 A	24-03-2021
		SG 11202012074V A	28-01-2021
		US 2022073581 A1	10-03-2022
		WO 2020011868 A1	16-01-2020
WO 2015187977 A1	10-12-2015	AU 2015269333 A1	15-12-2016
		AU 2020210315 A1	27-08-2020
		BR 112016028520 A2	24-10-2017
		CA 2950754 A1	10-12-2015
		CN 106795224 A	31-05-2017
		CN 113583104 A	02-11-2021
		EA 201692529 A1	31-05-2017
		EA 202090632 A1	31-07-2020
		EP 3152237 A1	12-04-2017
		EP 3721892 A1	14-10-2020
		JP 6568110 B2	28-08-2019
		JP 6856716 B2	07-04-2021
		JP 2017518303 A	06-07-2017
		JP 2019203017 A	28-11-2019
		JP 2021095416 A	24-06-2021
		KR 20170005891 A	16-01-2017
		KR 20200017548 A	18-02-2020
		KR 20200084064 A	09-07-2020
		KR 20210119546 A	05-10-2021
		MA 51074 A	14-10-2020
		MA 51075 A	14-10-2020
		US 2016185836 A1	30-06-2016
		US 2018340013 A1	29-11-2018
		WO 2015187977 A1	10-12-2015
US 9879077 B2	30-01-2018	AU 2014312456 A1	03-03-2016
		BR 112016004355 A2	17-10-2017
		CA 2922618 A1	05-03-2015
		CN 105899532 A	24-08-2016
		DK 3039038 T3	08-02-2021
		EP 3039038 A1	06-07-2016

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2023/065930

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 3632930 A1	08-04-2020
		ES 2866848 T3	19-10-2021
		HK 1223107 A1	21-07-2017
		JP 6422977 B2	14-11-2018
		JP 6800180 B2	16-12-2020
		JP 2016528922 A	23-09-2016
		JP 2018172391 A	08-11-2018
		KR 20150026997 A	11-03-2015
		KR 20150118565 A	22-10-2015
		MX 371328 B	27-01-2020
		PH 12016500403 A1	16-05-2016
		PL 3039038 T3	19-04-2021
		RU 2016105586 A	04-10-2017
		UA 117493 C2	10-08-2018
		US 2016376350 A1	29-12-2016
		US 2018030127 A1	01-02-2018
		WO 2015030539 A1	05-03-2015
